References
- Guideline on good pharmacovigilance practices (GVP): module V - risk management systems (Rev 1). 2014. [cited 2015 Aug 4]. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp&mid=WC0b01ac058058f32c
- Regulation (EC) No 726/2004 of the European parliament and of the council of March 2004 laying down community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European medicines agency. 2013; [cited 2015 Aug 4]. Available at: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2004_726/reg_2004_726_en.pdf
- Directive 2001/83/EC of the European parliament and of the council of 6 November 2001 on the community code relating to medicinal products for human use. 2012; [cited 2015 Aug 4]. Available at: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf
- Zomerdijk IM, Sayed-Tabatabaei FA, Trifiro G, et al. Risk minimization activities of centrally authorized products in the EU: a descriptive study. Drug Saf. 2012 Apr 1;35(4):299–314. PubMed PMID: 22339506; eng.
- Guideline on good pharmacovigilance practices (GVP): module XVI - risk minimisation measures: selection of tools and effectiveness indicators (Rev 1). 2014. [cited 2015 Aug 4]. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp&mid=WC0b01ac058058f32c
- Rubino A, Artime E. A descriptive review of additional risk minimisation measures applied to EU centrally authorised medicines 2006–2015. Expert Opin Drug Saf. 2017 Aug;16(8):877–884. PubMed PMID: 28548608.
- Keddie S. A descriptive study of additional risk minimization measures included in risk management plans reviewed by the United Kingdom regulatory authority. Pharmaceut Med. 2013;27(1):25–34.
- Wu J, Juhaeri J. The US food and drug administration’s Risk Evaluation and Mitigation Strategy (REMS) program – current status and future direction. Clin Ther. 2016;38(12):2526–2532.
- Slomiany M, Bitar R, Kruse S, et al. Drug safety and the cost of monitoring: the role of REMS in risk management. Ther Innovation Regul Sci. 2015;49(4):514–523.
- Borg JJ, Aislaitner G, Pirozynski M, et al. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to?: a review of the new EU legislation on pharmacovigilance. Drug Saf. 2011;34(3):187–197.
- Borg JJ, Tanti A, Kouvelas D, et al. European Union pharmacovigilance capabilities: potential for the new legislation. Ther Adv Drug Saf. 2015;6(4):120–140.
- Commission regulation (EC) No 507/2006 of 29 March 2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of regulation (EC) No 726/2004 of the European parliament and of the council. 2006. [cited 2015 Aug 4]. Available at: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2006_507/reg_2006_507_en.pdf
- Jandoc R, Burden AM, Mamdani M, et al. Interrupted time series analysis in drug utilization research is increasing: systematic review and recommendations. J Clin Epidemiol. 2015 2015/08/01/;68(8):950–956.
- Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol. 2017 Feb;46(1):348–355. PubMed PMID: 27283160; PubMed Central PMCID: PMCPMC5407170. eng.
- Davis C, Abraham J. A comparative analysis of risk management strategies in European union and united states pharmaceutical regulation. Health Risk Soc. 2011;13(5):413–431.
- Eichler H-G, Abadie E, Raine JM, et al. Safe drugs and the cost of good intentions. New England J Med. 2009;360(14):1378–1380. PubMed PMID: 19339718.
- Methodology WCCfDS. Guidelines for ATC classification and DDD assignment 2017. 2016. [cited 2018 Jan]. Available at: https://www.whocc.no/atc_ddd_index_and_guidelines/atc_ddd_index/
- Smith MY, Attig B, McNamee L, et al. Tuberculosis screening in prescribers of anti-tumor necrosis factor therapy in the European Union. Int J Tuberculosis Lung Dis. 2012;16(9):1168–1173.
- Lim CH, Chen HH, Chen YH, et al. The risk of tuberculosis disease in rheumatoid arthritis patients on biologics and targeted therapy: a 15-year real world experience in Taiwan. PLoS One. 2017;12:6.
- Agyemang E, Bailey L, Talbot J. Additional risk minimisation measures for medicinal products in the European Union: a review of the implementation and effectiveness of measures in the United Kingdom by one marketing authorisation holder. Pharmaceut Med. 2017;31(2):101–112.
- Smith MY, Morrato E. Advancing the field of pharmaceutical risk minimization through application of implementation science best practices. Drug Saf. 2014;37(8):569–580.
- Morrato EH, Smith MY. Integrating risk minimization planning throughout the clinical development and commercialization lifecycle: an opinion on how drug development could be improved. Ther Clin Risk Manag. 2015;11((Morrato E.H.,[email protected]) Colorado School of Public Health, University of Colorado, Anschutz Medical Campus, Aurora, United States):339–348.
- Banerjee AK, Zomerdijk IM, Wooder S, et al. Post-approval evaluation of effectiveness of risk minimisation: methods, challenges and interpretation. Drug Saf. 2014 Jan;37(1):33–42. PubMed PMID: 24357107; eng.
- Nyeland ME, Laursen MV, Callréus T. Evaluating the effectiveness of risk minimisation measures: the application of a conceptual framework to Danish real-world dabigatran data. Pharmacoepidemiol Drug Saf. 2017;26(6):607–614.
- Zomerdijk IM, Trifiro G, Sayed-Tabatabaei FA, et al. Additional risk minimisation measures in the EU - are they eligible for assessment? Pharmacoepidemiol Drug Saf. 2013 Oct;22(10):1046–1053. PubMed PMID: 23946274; eng.